Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT06233695 Completed - Heart Failure Clinical Trials

Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure

GBDAL-HF
Start date: October 15, 2022
Phase:
Study type: Observational

Heart failure (HF) is a major healthcare problem. In patients with Heart Failure with Reduced Ejection Fraction (HFrEF), aldosterone antagonists reduce mortality and hospitalization rate. Gender-related differences have been described in the regulation of renin angiotensin aldosterone system (RAAS), which is at the core of the pathophysiology of HF. Regarding gender-related differences in the use of MRAs, less is known about the effects of androgens on RAAS. In this single-center prospective cohort, a total of 100 adult (≥ 18 years) ambulatory patients of both sexes with the diagnosis of HF with HFrEF (LVEF≤ 40%) and NYHA class II-IV under optimized medical therapy started an aldosterone antagonist are enrolled and followed-up for 6 months. Patients are categorized according to their apparent sexual gender into two groups: the male group and the female group.

NCT ID: NCT06228807 Completed - Clinical trials for Heart Failure With Preserved Ejection Fraction

Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF

Start date: October 5, 2015
Phase:
Study type: Observational

Heart failure with preserved ejection fraction (HFpEF) is a prevalent form of heart failure characterized by impaired left ventricle pressures and diastolic dysfunction. Despite its increasing prevalence, effective treatment options for HFpEF remain limited, probably due to its heterogenous underlying pathological etiology involving chronic systemic inflammation and metabolic dysregulation. Identifying new predictors of poor prognosis is crucial for risk stratification and tailored management.

NCT ID: NCT06227819 Completed - Heart Failure Clinical Trials

BVA-200 vs BVA-100 Validation Study

Start date: May 23, 2023
Phase:
Study type: Observational

The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device. Data from this study may be pooled with data from studies with similar design conducted at other sites, for the purposes of an FDA medical device submission.

NCT ID: NCT06200246 Completed - Clinical trials for Heart Failure, Left-sided

Cardio-vascular Energy Transfer and Ventriculo-arterial Coupling in Heart Failure

Start date: October 1, 2022
Phase:
Study type: Observational

The goal of this pilot study is to investigate energy transfer fram the ventricle to the arteries in patients with heart failure, primary by investigating the total power.

NCT ID: NCT06197256 Completed - COVID-19 Clinical Trials

Cardiac Dysfunction in Critically Ill Covid-19 Patients

Start date: May 7, 2020
Phase:
Study type: Observational

We conducted an observation sub-study of the prospective randomized controlled trial "High Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure", in which we analysed the echocardiographic data collected both at baseline when patients where included and 3-5 days later for followup.

NCT ID: NCT06169345 Completed - Heart Failure Clinical Trials

The Long-term Course of Moderate Tricuspid Regurgitation

LOCOMOTRI
Start date: May 1, 2021
Phase:
Study type: Observational

To evaluate the long-term clinical outcome of a cohort of patients suffering from moderate tricuspid regurgitation (TR), regardless of its etiology.

NCT ID: NCT06099028 Completed - Heart Failure Clinical Trials

Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China

Start date: September 1, 2021
Phase:
Study type: Observational

This is a retrospective, researcher-initiated, database-based study that will retrospectively observe the treatment and medication patterns of about 22,500 patients with heart failure from 25 heart failure centers and 25 non-heart failure centers in the database of heart failure center. The proportion of patients with heart failure treatment drugs reaching the target dose recommended in the guidelines and discontinuation rate will be observed at 1 month, 3 months and 12 months follow up time point. The purpose of this study is to illustrate the current HF treatment status in HF center hospitals and non-HF center hospitals, which may provide insights for improving the clinical practice of heart failure treatment in China, and promote the standardization of heart failure treatment in China.

NCT ID: NCT06092658 Completed - Clinical trials for Analyze Etiology, Comorbidities, Clinical Characteristics

Cohort Study of Chronic Heart Failure

Start date: November 20, 2012
Phase:
Study type: Observational

The purpose is to understand the clinical characteristics of chronic heart failure as soon as possible, analyze the etiology, comorbidities, clinical characteristics, and treatment of heart failure patients, observe the gap between real-world clinical practice and guideline recommendations, and provide reference for the improvement of heart failure prevention and treatment in China.

NCT ID: NCT06070506 Completed - Heart Failure Clinical Trials

Heart Failure With Improved Ejection Fraction and Deep Learning

Start date: March 1, 2022
Phase:
Study type: Observational

The aim of this study was to design a deep learning-based trained model to assist in HFimpEF diagnosis.

NCT ID: NCT06068725 Completed - Heart Failure Clinical Trials

The Effect of Video Training o Symptom Management With Heart Failure

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this clinical study is to compare the effect of video-assisted training on the quality of life and symptom management of patients over the age of 65. The main questions it aims to answer are: -Is there a difference between symptom management and quality of life between the first and last follow-up periods of patients in the application and control groups?